Cite this paper
nullD. Parida, K. Wakame and T. Nomura, "Integrating Complimentary and Alternative Medicine in Form of Active Hexose Co-Related Compound (AHCC) in the Management of Head & Neck Cancer Patients," International Journal of Clinical Medicine
, Vol. 2 No. 5, 2011, pp. 588-592. doi: 10.4236/ijcm.2011.25097
 National Cancer Registry P Publication 2007.
 P. Jha, B. Jacob, V. Gajalakshmi, P. C. Gupta, N. Dhingra, R. Kumar, D. N. Sinha, R. P. Dikshit, D. K. Parida, R. Kamadod, J. Boreham, R. Peto and RGI-CGHR Investigators, “A Nationally Representative Case-Control Study of Smoking and Death in India,” New England Journal of Medicine, Vol. 358, No. 11, 2008, pp. 1137-1147.
 Y. Gao, D. Zhang, B. X. Sun, H. Fujii, K. Kosuna and Z. Yin, “Active Hexose Correlated Compound Enhances Tumor Surveillance through Regulating both Innate and Adaptive Immune Responses,” Cancer Immunology Immunotherapy, Vol. 55, No. 10, 2006, pp. 1258-1266.
 N. Terakawa, Y. Matsui, S. Satoi, et al., “Immunological Effect of Active Hexose Correlated Compound (AHCC) in Healthy Volunteers: A Double-Blind, Placebo-Controlled Study,” Nutrition and Cancer, Vol. 60, No. 5, 2008, pp. 643-651. doi:10.1080/01635580801993280
 S. Wasser and A. Weis, “Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective,” Critical Reviews in Immunology, Vol. 19, No. 1, 1999, pp. 65-96.
 R. Burikhanov, K. Wakame, Y. Igarashi, S. Wang, S. Matsuzaki, “Suppressive Effect of Active Hexose Correlated Compound on Thymic Apoptosis Induced by Dexamethasone in the Rat,” Endocrine Research, Vol. 34, 2000, pp. 181-188.
 T. Nomura, et al., “Antiteratogenic Effects of Tumor Inhibitors, Caffeine, Antipain, and Retinoic Acid in Mice,” Cancer Research, Vol. 43, 1983, pp. 5156-5162.
 Y. Matsui, J. Uhara, S. Satoi, M. Kaibori, H. Yamada, H. Kitade, A. Imamura, S. Takai, Y. Kawaguchi, A. Kwon and Y. Kamiyama, “Improved Prognosis of Postoperative Hepatocellular Carcinoma Patients When Treated with Functional Foods: A Prospective Cohort Study,” Journal of Hepatology, Vol. 37, No. 1, 2002, pp. 78-86.
 C. Suwanna, et al., “Prognostic Improvement of Patients with Advanced Liver Cancer after Active Hexose Correlated Compound (AHCC) Treatment,” Asian Pacific Journal of Allergy & Immunology, Vol. 24, No. 1, 2006, pp. 33-45.
 E. L. Spierings, H. Fujii, B. Sun and T. Walshe, “A Phase I Study of the Safety of the Nutritional Supplement, Active Hexose Correlated Compound (AHCC) in Healthy Volunteers,” Journal of Nutritional Science & Vitaminology, Vol. 53, No. 6, 2007, pp. 536-539.
 I. Hyodo, N. Amano and K. Eguchi, “Nationwide Survey on Complementary and Alternative Medicine in Cancer Patients in Japan,” Journal of Clinical Oncology, Vol. 23, No. 12, 2005, pp. 2645-2654.
 K. Matsushita, et al., “Combination Therapy of Active Hexose Correlated Compound (AHCC) Plus UFT Significantly Reduces the Metastasis of Rat Mammary Carcinoma,” Anti-Cancer Drugs, Vol. 9, 1998, pp. 343-350.
 A. Hirose, E. Sato, H. Fujii, S. Buxiang, H. Nishioka and O. I. Aruoma, “The Influence of Active Hexose Correlated Compound (AHCC) on Cisplatin-Evoked Chemotherapeutic and Side Effects in Tumor-Bearing Mice,” Toxicology and Applied Pharmacology, Vol. 222, No. 2, 2007, pp. 152-158. doi:10.1016/j.taap.2007.03.031
 C. Mach, H. Fujii, K. Wakame and J. Smith, “Evaluation of Active Hexose Correlated Compound Hepatic Metabolism and Potential for Drug Interactions with Chemotherapy Agents,” Journal of the Society for Integrative Oncology, Vol. 6, No. 3, 2008, pp. 105-109.
 K. Shigama, A. Nakaya, K. Wakame, H. Nishioka and H. Fujii, “Alleviating Effect of Active Hexose Correlated Compound (AHCC) for Anticancer Drug-Induced Side Effects in Non-Tumor-Bearing Mice,” Journal of Experimental Therapeutics and Oncology, Vol. 8, No. 1, 2009, pp. 43-51.